King of Prussia, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biotechnology company Alector announced today that the drug, latozinemab, failed to meet the criteria for safety and efficacy in a Phase 3 clinical trial. The study investigated the drug as an intervention for cases of FTD caused by a variant of the gene GRN. Three genes, GRN, MAPT, and C9orf72, cause the majority of genetic FTD—itself roughly 20% of FTD cases. “Even though this trial shows that latozinemab is not the treatment FTD-GRN families had hop ...